image

Tuberculosis (TB) Diagnostics Market Report Scope & Overview:

The Tuberculosis (TB) Diagnostics Market size was valued at USD 2.39 billion in 2023 and is expected to reach USD 3.61 billion By 2031 with an emerging CAGR of 5.3% over the forecast period of 2024-2031.

The Tuberculosis (TB) Diagnostics Market refers to the market for diagnostic equipment and tests used in the detection and diagnosis of tuberculosis, a contagious bacterial infection caused by Mycobacterium tuberculosis. TB diagnostics serve a critical role in identifying active TB cases, assessing Product response, and restricting the spread of the illness. The market covers a range of diagnostic methods and products designed to identify TB infections. Sputum samples are examined under a microscope using a traditional diagnostic approach to look for the presence of TB germs. assays carried out on blood samples that look for antibodies produced in response to TB infection. Although frequently employed as screening tools, these tests have limitations in terms of accuracy and their inability to distinguish between latent and active infections.

Tuberculosis (TB) Diagnostics Market Revenue Analysis

Get More Information on Tuberculosis (TB) Diagnostics Market - Request Sample Report

The global incidence of TB, raising awareness of early diagnosis, technical improvements, and government attempts to combat the disease are some of the reasons driving the TB diagnostics market. The market is characterised by ongoing research and development projects to provide diagnostic technologies that are more precise, quick, and economical. In order to increase access to testing and early detection, efforts are being concentrated on point-of-care diagnostics that can be used in environments with limited resources. The TB diagnostics market has regional variations, with high-burden nations like India, China, and Sub-Saharan Africa having significant market potential due to the incidence of TB. However, the market is international in scope, and TB diagnostic technologies are being developed, produced, and used by healthcare organisations all over the world.

Market Dynamics:

  • A serious worldwide health concern, tuberculosis has a high disease burden in many nations.

  • Point-of-care the importance of TB diagnostics, which offer quick results at the point of care, is growing.

  • International collaboration and partnerships.

Innovative TB diagnostic technologies are developed and commercialised as a result of partnerships between research institutes, diagnostic firms, and international health organisations. These collaborations extend the range of TB diagnosis choices by quickening the release of new diagnostic equipment onto the market.

Restrain:

  • The availability of high-quality TB diagnostic services is sometimes constrained, especially in underdeveloped and isolated areas.

It can be difficult to diagnose latent TB infection, which occurs when a person has TB germs but does not exhibit any obvious symptoms. The price of TB diagnostic tests can be a considerable obstacle, particularly in areas with limited resources where affordability is a key factor.

Opportunity:

  • There is an increasing demand for point-of-care TB diagnostic tests that can offer speedy and accurate results at the site of care.

  • Continued innovation in TB diagnostic technology is necessary to address the limitations of present testing.

  • Point-of-Care Platforms and TB Diagnostics Integration.

By combining TB diagnostics with existing or future point-of-care platforms, such as mobile health technology or portable molecular testing instruments, the accessibility and efficacy of TB diagnosis can be increased. These integrated platforms can improve disease surveillance and patient management by enabling real-time data collection, remote monitoring, and seamless system connections with healthcare systems.

Challenge:

  • It can be difficult to gather and handle the right samples, including sputum specimens, for TB diagnosis.

The use of sophisticated TB diagnostic technology is hampered by resource shortages, including funding restrictions, laboratory capacity, and a lack of skilled workers.

Impact of Covid-19:

In addition to outlining the key market trends, the Tuberculosis (TB) Diagnostics Market Research Reports go into great detail about the effects of the coronavirus. Insights, analysis, projections, and predictions on COVID-19's effect on the industry are provided in the report's research It is clear that the current crisis is fundamentally different from earlier recessions, given the scope of the pandemic's disruption. The sudden drop in demand and rising unemployment will alter the business climate. Businesses may forge new paths in this unsettling climate by embracing cutting-edge concepts like advancing towards localization, cash conservation, supply chain resilience, and innovation.

A recent study found that TB cases are present in 0.38 to 4.50% of COVID-19 patients. Experts and academics have proposed that tuberculosis amplifies the effects of COVID-19. Both illnesses have pulmonary complications, which is quite concerning in the COVID-19 pandemic.

Impact of Russia and Ukraine-War:

In the WHO European Region, Ukraine has one of the highest TB incidence rates and one of the highest rates of MDR-TB (multidrug-resistant TB). In 2020, 4,257 people with MDR-TB were reported in Ukraine, compared to 566 patients across the entire European Union and European Economic Area, according to the most recent WHO report. Up until recently, there were severe shortages of TB diagnoses and anti-TB medications in Ukraine. To improve the Product outcomes of MDR-TB patients in Ukraine, a number of significant control interventions have been put in place over the past five years, including the availability of Xpert MTB/Rif and Xpert MTB/XDR (Cepheid; Sunnyvale, CA, USA) and a steady supply of WHO-recommended medications.

Civilian infrastructure, including healthcare facilities, has been partially devastated after the military invasion by the Russian Federation on February 24, 2022. More than 9 million people, or one-fourth of Ukraine's population, will be displaced by the middle of 2022, with most of them having departed the nation. People have spent a lot of time in congested, poorly ventilated air raid shelters, which create the perfect environment for the spread of Mycobacterium tuberculosis. 4 It was believed that this military war would have an impact on the availability of TB diagnoses and Products.5 We conducted a point prevalence study on the accessibility of inpatient and outpatient care, diagnostics, and anti-TB medications to evaluate the effects of the conflict.

Key Market Segmentation

By Type:

By End User:

  • Hospitals

  • Diagnostics

  • Laboratories

REGIONAL COVERAGE:

  • North America

    • USA

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • The Netherlands

    • Rest of Europe

  • Asia-Pacific

    • Japan

    • South Korea

    • China

    • India

    • Australia

    • Rest of Asia-Pacific

  • The Middle East & Africa

    • Israel

    • UAE

    • South Africa

    • Rest of the Middle East & Africa

  • Latin America

    • Brazil

    • Argentina

    • Rest of Latin America

Regional Analysis:

North America:

Compared to other locations, North America has a relatively low TB burden. The healthcare systems in the US and Canada are well-established, and their laboratory infrastructure is state-of-the-art. The use of cutting-edge diagnostic technology and a focus on point-of-care testing are characteristics of this industry. The market for TB diagnostics in North America is expanding thanks to research and development initiatives, industrial and academic partnerships, and government programmes.

Asia Pacific:

Asia Pacific has the largest prevalence of TB in the world, with high-burden nations including India, China, and Indonesia. The enormous number of people affected by TB in this area, raising awareness, and government measures to manage the disease are what is driving the market. However, limitations include limited access to high-quality diagnostic services, a weak healthcare infrastructure, and problems with affordability. A variety of conventional and cutting-edge diagnostic techniques are used in the market, and efforts are being made to increase access to molecular diagnostics and point-of-care testing.

Tuberculosis-TB-Diagnostics-Market-By-Region

Get Customized Report as per Your Business Requirement - Request For Customized Report

Key Players:

The major players are Akonni Biosystems Inc., Alere Inc., Par Pharmaceutical, Lionex GmbH, Creative Diagnostics, Abbott Laboratories, BioMerieux SA, Cepheid, Hologic Inc., F. Hoffmann-La Roche Ltd and other players are listed in the final reports.

Alere Inc-Company Financial Analysis

Company Landscape Analysis

Recent Developments:

In July 2020: Cepheid, a subsidiary of Danaher, launched the Xpert MTB/XDR Test in collaboration with the Foundation for Innovative New Diagnostics (FIND). The test can expand the drug-resistance TB profile in about 90 minutes.

In May 2021: F. Hoffmann-La Roche Ltd. teamed with GenMark Diagnostics. Hoffman F. Hoffmann-La Roche Ltd. finalised the acquisition of GenMark for almost USD 1.8 billion. Through the acquisition, F. Hoffmann-La Roche Ltd. wants to expand its molecular diagnostics portfolio with GenMark’s syndromic testing capabilities.

Tuberculosis (TB) Diagnostics Market Report Scope:

Report Attributes Details
Market Size in 2023  US$ 2.39 Bn
Market Size by 2031  US$ 3.61 Bn
CAGR   CAGR of  5.3% From 2024 to 2031
Base Year  2023
Forecast Period  2024-2031
Historical Data  2020-2022
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Type (Culture-Based Diagnostics, Sputum Smear Microscopy, Rapid Molecular Diagnostics)
• By End User (Hospitals, Diagnostics, and Laboratories)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles Akonni Biosystems Inc., Alere Inc., Par Pharmaceutical, Lionex GmbH, Creative Diagnostics, Abbott Laboratories, BioMerieux SA, Cepheid, Hologic Inc., F. Hoffmann-La Roche Ltd
Key Drivers • A serious worldwide health concern, tuberculosis has a high disease burden in many nations.
• Point-of-care the importance of TB diagnostics, which offer quick results at the point of care, is growing.
Market Opportunities • There is an increasing demand for point-of-care TB diagnostic tests that can offer speedy and accurate results at the site of care.
• Continued innovation in TB diagnostic technology is necessary to address the limitations of present testing.

 

Frequently Asked Questions

Ans: The Tuberculosis (TB) Diagnostics Market is to Hit USD 3.61 Billion By 2031.

Ans: The Tuberculosis (TB) Diagnostics Market is to grow at 5.3% Over the Forecast Period 2024-2031.

Ans: The Tuberculosis (TB) Diagnostics Market size was valued at USD 2.39 Billion in 2023.

Ans:  The latest TB diagnostics is Tuberculosis antigen-based skin tests (TBST).

Ans: Akonni Biosystems Inc., Alere Inc., Par Pharmaceutical, Lionex GmbH, Creative Diagnostics, Abbott Laboratories, BioMerieux SA, Cepheid, Hologic Inc., F. Hoffmann-La Roche Ltd

Table of Contents

1. Introduction 
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions

2. Research Methodology

3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges

4. Impact Analysis
4.1 COVID 19 Impact Analysis
4.2 Impact of the Ukraine- Russia war
4.3 Impact of ongoing Recession 
4.3.1 Introduction
4.3.2 Impact on major economies
4.3.2.1 US
4.3.2.2 Canada
4.3.2.3 Germany
4.3.2.4 France
4.3.2.5 United Kingdom
4.3.2.6 China
4.3.2.7 Japan
4.3.2.8 South Korea
4.3.2.9 Rest of the World

5. Value Chain Analysis

6. Porter’s 5 forces model

7. PEST Analysis

8.  Tuberculosis (TB) Diagnostics Market Segmentation, By Type
8.1 Culture-Based Diagnostics
8.2 Sputum Smear Microscopy
8.3 Rapid Molecular Diagnostics

9.  Tuberculosis (TB) Diagnostics Market Segmentation, By End User
9.1 Hospitals
9.2 Diagnostics
9.3 Laboratories

10. Regional Analysis
10.1 Introduction
10.2 North America
10.2.1 North America Tuberculosis (TB) Diagnostics Market by Country
10.2.2North America Tuberculosis (TB) Diagnostics Market by Type
10.2.3 North America Tuberculosis (TB) Diagnostics Market by End-User
10.2.4 USA    
10.2.4.1 USA Tuberculosis (TB) Diagnostics Market by Type
10.2.4.2 USA Tuberculosis (TB) Diagnostics Market by End-User    
10.2.7 Canada
10.2.7.1 Canada Tuberculosis (TB) Diagnostics Market by Type    
10.2.7.2 Canada Tuberculosis (TB) Diagnostics Market by End-User
10.2.8 Mexico
10.2.8.1 Mexico Tuberculosis (TB) Diagnostics Market by Type    
10.2.8.2 Mexico Tuberculosis (TB) Diagnostics Market by End-User
10.3 Europe 
10.3.1 Europe Tuberculosis (TB) Diagnostics Market by Country
1.3.3.2 Europe Tuberculosis (TB) Diagnostics Market by Type    
10.3.3 Europe Tuberculosis (TB) Diagnostics Market by End-User
10.3.6 Germany
10.3.6.1 Germany Tuberculosis (TB) Diagnostics Market by Type    
10.3.6.2 Germany Tuberculosis (TB) Diagnostics Market by End-User
10.3.7 UK
10.3.7.1 UK Tuberculosis (TB) Diagnostics Market by Type    
10.3.7.2 UK Tuberculosis (TB) Diagnostics Market by End-User
10.3.8 France
10.3.8.1 France Tuberculosis (TB) Diagnostics Market by Type
10.3.8.2 France Tuberculosis (TB) Diagnostics Market by End-User
10.3.9 Italy
10.3.9.1 Italy Tuberculosis (TB) Diagnostics Market by Type
10.3.9.2 Italy Tuberculosis (TB) Diagnostics Market by End-User
10.3.10 Spain
10.3.10.1 Spain Tuberculosis (TB) Diagnostics Market by Type    
10.3.10.2 Spain Tuberculosis (TB) Diagnostics Market by End-User 
10.3.11 The Netherlands
10.3.11.1 Netherlands Tuberculosis (TB) Diagnostics Market by Type    
10.3.11.2 Netherlands Tuberculosis (TB) Diagnostics Market by End-User
10.3.11 Rest of Europe
10.3.11.1 Rest of Europe Tuberculosis (TB) Diagnostics Market by Type
10.3.11.2 Rest of Europe Tuberculosis (TB) Diagnostics Market by End-User
10.4 Asia-Pacific
10.4.1 Asia Pacific Tuberculosis (TB) Diagnostics Market by Country
10.4.2 Asia Pacific Tuberculosis (TB) Diagnostics Market by Type
10.4.3 Asia Pacific Tuberculosis (TB) Diagnostics Market by End-User
10.4.6 Japan
10.4.6.1 Japan Tuberculosis (TB) Diagnostics Market by Type    
10.4.6.2 Japan Tuberculosis (TB) Diagnostics Market by End-User
10.4.7 South Korea
10.4.7.1 South Korea Tuberculosis (TB) Diagnostics Market by Type
10.4.7.2 South Korea Tuberculosis (TB) Diagnostics Market by End-User
10.4.8 China
10.4.8.1 China Tuberculosis (TB) Diagnostics Market by Type    
10.4.8.2 China Tuberculosis (TB) Diagnostics Market by End-User    
10.4.9 India
10.4.9.1 India Tuberculosis (TB) Diagnostics Market by Type    
10.4.9.2 India Tuberculosis (TB) Diagnostics Market by End-User
10.4.10 Australia
10.4.10.1 Australia Tuberculosis (TB) Diagnostics Market by Type
10.4.10.2 Australia Tuberculosis (TB) Diagnostics Market by End-User    
10.4.11 Rest of Asia-Pacific
10.4.11.1 APAC Tuberculosis (TB) Diagnostics Market by Type    
10.4.11.2 APAC Tuberculosis (TB) Diagnostics Market by End-User    
10.5 The Middle East & Africa
10.5.1 The Middle East & Africa Tuberculosis (TB) Diagnostics Market by Country
10.5.2 The Middle East & Africa Tuberculosis (TB) Diagnostics Market by Type    
10.5.3 The Middle East & Africa Tuberculosis (TB) Diagnostics Market by End-User
10.5.6 Israel
10.5.6.1 Israel Tuberculosis (TB) Diagnostics Market by Type    
10.5.6.2 Israel Tuberculosis (TB) Diagnostics Market by End-User    
10.5.7 UAE
10.5.7.1 UAE Tuberculosis (TB) Diagnostics Market by Type
10.5.7.2 UAE Tuberculosis (TB) Diagnostics Market by End-User
10.5.8 South Africa
10.5.8.1 South Africa Tuberculosis (TB) Diagnostics Market by Type
10.5.8.2 South Africa Tuberculosis (TB) Diagnostics Market by End-User
10.5.9 Rest of Middle East & Africa
10.5.9.1 Rest of Middle East & Asia Tuberculosis (TB) Diagnostics Market by Type
10.5.9.2 Rest of Middle East & Asia Tuberculosis (TB) Diagnostics Market by End-User
10.6 Latin America
10.6.1 Latin America Tuberculosis (TB) Diagnostics Market by Country
10.6.2 Latin America Tuberculosis (TB) Diagnostics Market by Type
10.6.3 Latin America Tuberculosis (TB) Diagnostics Market by End-User
10.6.6 Brazil
10.6.6.1 Brazil Tuberculosis (TB) Diagnostics Market by Type
10.6.6.2 Brazil Africa Tuberculosis (TB) Diagnostics Market by End-User
10.6.7 Argentina
10.6.7.1 Argentina Tuberculosis (TB) Diagnostics Market by Type
10.6.7.2 Argentina Tuberculosis (TB) Diagnostics Market by End-User
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Tuberculosis (TB) Diagnostics Market by Type
10.6.8.2 Rest of Latin America Tuberculosis (TB) Diagnostics Market by End-User

11. Company profile
11.1 Akonni Biosystems Inc
11.1.1 Market Overview
11.1.2 Financials
11.1.3 Product/Services/Offerings
11.1.4 SWOT Analysis
11.1.5 The SNS View
11.2 Alere Inc
11.2.1 Market Overview
11.2.2 Financials
11.2.3 Product/Services/Offerings
11.2.4 SWOT Analysis
11.2.5 The SNS View
11.3 Par Pharmaceutical
11.3.1 Market Overview
11.3.2 Financials
11.3.3 Product/Services/Offerings
11.3.4 SWOT Analysis
11.3.5 The SNS View
11.4 Lionex GmbH
11.4.1 Market Overview
11.4.2 Financials
11.4.3 Product/Services/Offerings
11.4.4 SWOT Analysis
11.4.5 The SNS View
11.5 Creative Diagnostics
11.5.1 Market Overview
11.5.2 Financials
11.5.3 Product/Services/Offerings
11.5.4 SWOT Analysis
11.5.5 The SNS View
11.6 Abbott Laboratories
11.6.1 Market Overview
11.6.2 Financials
11.6.3 Product/Services/Offerings
11.6.4 SWOT Analysis
11.6.5 The SNS View
11.7 BioMerieux SA
11.7.1 Market Overview
11.7.2 Financials
11.7.3 Product/Services/Offerings
11.7.4 SWOT Analysis
11.7.5 The SNS View
11.8 Cepheid
11.8.1 Market Overview
11.8.2 Financials
11.8.3 Product/Services/Offerings
11.8.4 SWOT Analysis
11.8.5 The SNS View
11.9 Hologic Inc
11.9.1 Market Overview
11.9.2 Financials
11.9.3 Product/Services/Offerings
11.9.4 SWOT Analysis
11.9.5 The SNS View
11.9 F. Hoffmann-La Roche
11.9.1 Market Overview
11.9.2 Financials
11.9.3 Product/Services/Offerings
11.9.4 SWOT Analysis
11.9.5 The SNS View

12. Competitive Landscape
12.1 Competitive Benchmarking
12.2 Market Share Analysis
12.3 Recent Developments

13. Used Cases and Best Practices

14. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone